Virtu Financial’s Supernus Pharmaceuticals SUPN Stock Holding History

Virtu Financial’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-3,421	Closed	-$205K	–	2168
2018 Q2	$205K	Buy	+3,421	New	+$177K	0.01%	1495

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Virtu Financial's SUPN Position: Q3 2018 in Review

Virtu Financial sold out of Supernus Pharmaceuticals (SUPN) in Q3 2018, closing a stake of 3,421 shares — an estimated $205K sold.

Virtu Financial first reported a position in SUPN in Q2 2018 and held it in 1 quarter. The position peaked at $205K in Q2 2018. 288 funds tracked by Wall St. Rank hold SUPN as of Q3 2018.

Virtu Financial reported no remaining Supernus Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Virtu Financial sold 3,421 Supernus Pharmaceuticals shares in Q3 2018, an estimated $205K.
Virtu Financial first reported a position in Supernus Pharmaceuticals in Q2 2018 and held it in 1 quarter.
Virtu Financial's Supernus Pharmaceuticals position peaked at $205K in Q2 2018.
288 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2018.

Based on Virtu Financial's 13F filing for Q3 2018, filed 13 Nov 2018.